|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||21.98|
|Dividend & Yield||8.22 (3.19%)|
|1y Target Est||N/A|
In the first half of 2017, Roche’s (RHHBY) Rituxan/MabThera reported revenues of CHF 3.8 billion, which is a 3.0% rise on a YoY basis.
In the first half of 2017, Roche’s (RHHBY) Ocrevus generated revenues of CHF 192.0 million.
Roche again disappointed this week with two studies on Tecentriq being put on partial hold while Pfizer's Bavencio received approval in Europe. TESARO's Zejula moved a step closer to approval.